Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082300 | 1.00 | KMT2A (0.51) | KMT2AMAPK1HSD11B1CTSKMAPT | |
| SCHEMBL2082032 | 0.81 | DRD4 (0.39) | HSD11B1UTS2RATM | |
| SCHEMBL2082035 | 0.81 | DRD4 (0.39) | HSD11B1UTS2RATM | |
| SCHEMBL6204711 | 0.81 | KMT2A (0.41) | KMT2AMAPK1HSD11B1CTSKUTS2R | |
| SCHEMBL6204716 | 0.81 | KMT2A (0.41) | KMT2AMAPK1HSD11B1CTSKUTS2R | |
| SCHEMBL6204713 | 0.81 | KMT2A (0.41) | KMT2AMAPK1HSD11B1CTSKUTS2R | |
| SCHEMBL4713900 | 0.79 | KMT2A (0.47) | KMT2AMAPK1CTSKUTS2RCTSS | |
| SCHEMBL4713895 | 0.79 | KMT2A (0.47) | KMT2AMAPK1CTSKUTS2RCTSS | |
| SCHEMBL31401115 | 0.78 | KMT2A (0.39) | KMT2ACTSKUTS2RCTSSDPP8 | |
| SCHEMBL6008976 | 0.78 | KMT2A (0.39) | KMT2ACTSKUTS2RCTSSDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902226-B2 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| EP-1336611-B1 | DEHALOGENO COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070123560-A1 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. | 2007-05-31 | — | — | US | disclosed |
| US-20040063754-A1 | Dehalogeno compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1336611-A1 | DEHALOGENO COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063754-A1 | Dehalogeno compounds | DEK, PGLS, RPS27L | KMT2A 2835/4885MAPK1 2078/4885HSD11B1 1295/4885 |
| US-20070123560-A1 | Dehalogeno-compounds | DEK, RPS27L, POLL | KMT2A 3591/4885MAPK1 2115/4885HSD11B1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.